|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:affects
|
not fully known
|
|
gptkbp:approves
|
gptkb:2020
gptkb:FDA
|
|
gptkbp:availability
|
prescription required
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Canada
gptkb:United_States
Phase 3
positive efficacy
acceptable safety profile
|
|
gptkbp:contraindication
|
pulmonary hypertension
history of cardiac valvulopathy
|
|
gptkbp:dosage_form
|
gptkb:liquid
|
|
gptkbp:drug_interactions
|
serotonergic drugs
other antiepileptic drugs
|
|
gptkbp:duration
|
as prescribed by a physician
|
|
gptkbp:effect_on_seizures
|
improves quality of life
reduces frequency
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:form
|
oral solution
|
|
gptkbp:funding
|
gptkb:pharmaceuticals
government grants
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Fintepla
|
|
gptkbp:indication
|
gptkb:Dravet_syndrome
gptkb:Lennox-Gastaut_syndrome
|
|
gptkbp:ingredients
|
fenfluramine
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
cardiac function
|
|
gptkbp:label
|
prescription only
|
|
gptkbp:manufacturer
|
Zogenix
|
|
gptkbp:marketed_as
|
gptkb:European_Union
gptkb:United_States
Zogenix
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_education
|
provided by healthcare providers
|
|
gptkbp:patient_population
|
gptkb:children
adults
adolescents
|
|
gptkbp:price
|
varies by insurance
|
|
gptkbp:provides_guidance_on
|
included in epilepsy treatment guidelines
|
|
gptkbp:research_focus
|
gptkb:epilepsy
seizure disorders
|
|
gptkbp:route_of_administration
|
oral
measured with a syringe
|
|
gptkbp:safety
|
Pregnancy Category C
|
|
gptkbp:service_frequency
|
twice daily
|
|
gptkbp:short_term_effects
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
sleep disturbances
decreased appetite
irritability
drowsiness
serious adverse events
mild adverse events
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:structure
|
C12 H16 F2 N2 O2
|
|
gptkbp:used_for
|
treatment of seizures
|
|
gptkbp:weight
|
246.26 g/mol
|